Literature DB >> 1391992

A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer.

J A Chapman1, M E Trudeau, K I Pritchard, C A Sawka, B G Mobbs, W M Hanna, H Kahn, D R McCready, L A Lickley.   

Abstract

Clinical studies usually employ Cox step-wise regression for multivariate investigations of prognostic factors. However, commercial packages now allow the consideration of accelerated failure time models (exponential, Weibull, log logistic, and log normal), if the underlying Cox assumption of proportional hazards is inappropriate. All-subset regressions are feasible for all these models. We studied a group of 378 node positive primary breast cancer patients accrued at the Henrietta Banting Breast Centre of Women's College Hospital, University of Toronto, between January 1, 1977, and December 31, 1986. 85% of these patients had complete prognostic factor data for multivariate analysis, and 96% of the patients were followed to 1990. There was evidence of marked departures from the proportional hazards assumption with two prognostic factors, number of positive nodes and adjuvant systemic therapy. The data strongly supported the log normal model. The all-subset regressions indicated that three models were similarly good. The variables 1) number of positive nodes, 2) tumour size, and 3) adjuvant systemic therapy were included in all three models along with one of three biochemical receptor variables 1) ER, 2) combined receptor (ER- PgR-; ER+PgR-; ER- PgR+; ER+PgR+; or 3) PgR. Better multivariate modeling was achieved by using quantitative prognostic factors, a check for appropriate underlying model-type, and all-subset variable selection. All-subset regressions should be considered for routine use with the many new prognostic factors currently under evaluation; it is very possible that there may not be a single model that is substantially better than others with the same number of variables.

Entities:  

Mesh:

Year:  1992        PMID: 1391992     DOI: 10.1007/bf01840839

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Assessment of response and recurrence in breast cancer.

Authors:  J L Hayward; J W Meakin; H J Stewart
Journal:  Semin Oncol       Date:  1978-12       Impact factor: 4.929

2.  ISMOD: an all-subsets regression program for generalized linear models. I. Statistical and computational background.

Authors:  J F Lawless; K Singhal
Journal:  Comput Methods Programs Biomed       Date:  1987-04       Impact factor: 5.428

3.  ISMOD: an all-subsets regression program for generalized linear models. II. Program guide and examples.

Authors:  J F Lawless; K Singhal
Journal:  Comput Methods Programs Biomed       Date:  1987-04       Impact factor: 5.428

4.  Prognostic value of estrogen and progesterone receptors in primary breast cancer.

Authors:  S Saez; F Cheix; B Asselain
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

5.  Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy.

Authors:  B Fisher; C K Redmond; D L Wickerham; H E Rockette; A Brown; J Allegra; D Bowman; D Plotkin; J Wolter
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

Review 6.  Steroid receptors and other prognostic factors in primary breast cancer.

Authors:  G M Clark; W L McGuire
Journal:  Semin Oncol       Date:  1988-04       Impact factor: 4.929

7.  Close correlation between progesterone receptor concentration and hormonal sensitivity in DMBA-induced mammary tumours of the rat.

Authors:  B G Mobbs
Journal:  Eur J Cancer Clin Oncol       Date:  1983-06
  7 in total
  3 in total

Review 1.  Prognostic factors: rationale and methods of analysis and integration.

Authors:  G M Clark; S G Hilsenbeck; P M Ravdin; M De Laurentiis; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

2.  Considerations in the statistical analysis of hemodialysis patient survival.

Authors:  Christos Argyropoulos; Chung-Chou H Chang; Laura Plantinga; Nancy Fink; Neil Powe; Mark Unruh
Journal:  J Am Soc Nephrol       Date:  2009-07-30       Impact factor: 10.121

3.  Identification of 6 Hub Proteins and Protein Risk Signature of Colorectal Cancer.

Authors:  Taohua Yue; Cheng Liu; Jing Zhu; Zhihao Huang; Shihao Guo; Yuyang Zhang; Hao Xu; Yucun Liu; Pengyuan Wang; Shanwen Chen
Journal:  Biomed Res Int       Date:  2020-12-08       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.